Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 15;20(3):602–611. doi: 10.1158/1535-7163.MCT-20-0412

Figure 3.

Figure 3.

Inhibition prior to tumor cell injection results in reduced tumor burden as well as ascites. (A) Schema of prophylactic dosing (B) Similar decease in ascites volume is seen with anti-TGF-β antibody administered prior to tumor challenge compared to treatment over five weeks. (C) Reduction in omental weights with single dose of anti-TGF-β antibody prior to tumor cell injection. (D-F) Again, favorable changes in T-cell response (D) increased proportion of CD8 T cells, (E) decrease in Tregs and (F) increased in CD8:Treg ratio, occur with this treatment strategy. (* p < 0.05, ** p < 0.01, bars represent SEM; dotted line – mean weight of naïve mouse omentum).